Yungjin Pharm Co Ltd
KRX:003520
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| KR |
|
Yungjin Pharm Co Ltd
KRX:003520
|
346B KRW |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
973.3B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
572.1B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
284.4B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
302.3B USD |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
217.3B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
227.3B CHF |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.3T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
153.8B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119.5B USD |
Loading...
|
Market Distribution
| Min | -168 471.3% |
| 30th Percentile | -2.9% |
| Median | 1.9% |
| 70th Percentile | 5.8% |
| Max | 21 012.5% |
Other Profitability Ratios
Yungjin Pharm Co Ltd
Glance View
Yungjin Pharm.Co., Ltd. engages in the development, production, and distribution of pharmaceuticals. The company is headquartered in Seoul, Seoul. The firm mainly manufactures and sells pharmaceutical products including antibiotics, respiratory drugs, anti-infective drugs, antipyretics, analgesics, central nervous system (CNS) drugs, gastrointestinal (GI) drugs, cardiovascular (CV) drugs, antihistamines, antifungals, antidiabetics, vitamin nutrients, antibiotic raw materials, and others. The firm also engages in the leasing of real estates.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Yungjin Pharm Co Ltd is -0.3%, which is above its 3-year median of -2.6%.
Over the last 3 years, Yungjin Pharm Co Ltd’s Net Margin has increased from -3.1% to -0.3%. During this period, it reached a low of -10.1% on Dec 31, 2022 and a high of 0.5% on Dec 31, 2024.
